Task Force developing European Guidelines for Neuromuscular Blockade Management

NEWS: Uppsala, November 19, 2020. Senzime AB (publ) are pleased to share that ESAIC, The European Society of Anaesthesiology and Intensive Care, has created a Task Force on Neuromuscular Blockade Management Guidelines.

Senzime’s Interim report January – September 2020

Press release: Uppsala, November 6, 2020. Senzime AB’s (publ) Interim report for January – September 2020 is now available on the company’s website  www.senzime.com

Nomination Committee in Senzime ahead of the 2021 Annual General Meeting

Press release: Uppsala, 4 November 2020. In accordance with the resolution at the Annual General Meeting of Senzime AB (publ) on May 14, 2020, the three largest shareholders have on 1 September 2020 appointed a Nomination Committee for the 2021 Annual General Meeting.

Senzime out-licenses OnZurf Probe on the European market

Press release: Uppsala, November 2, 2020. Senzime AB (publ) today announces the signing of an out-licensing agreement with the Italian company Moss S.p.A. As a result of the agreement, Moss will assume 10-year manufacturing and sales rights for the OnZurf Probe on the European market. The license agreement is estimated to generate more than SEK 100 million in license royalties over the term.

Senzime expands into the French market driven by new clinical Guidelines

Press release: Uppsala, October 29, 2020. Senzime AB (publ) today announces that the company has entered into an exclusive agreement with The Surgical Company (formerly Sebac) for the French market, and the first order to a university hospital in France is ready to be delivered.  Market entry is driven by the new clinical guidelines in France supporting the use of Senzime’s products in surgery.

Eva Walde strengthens Senzime’s Board of Directors

Press release: Uppsala, October 19, 2020. Senzime announces that Eva Walde is appointed new acting Board Member to be elected at the next shareholder’s meeting.

Senzime's first sales team in the USA in place

Press release: Uppsala, October 13, 2020. Senzime AB (publ) today announces that the company's American subsidiary - with the recruitment of the sixth employee - has reached the first established level of commercial org development in the US, as decided by the Board of Directors.

Senzime receives order from Switzerland

Press release: Uppsala, October 2, 2020. Senzime AB (publ) today announces that the company has received another order from its distributor Leuag in Switzerland. The order of TetraGraph systems with Philips Interface and disposable TetraSens sensors have been purchased to replace the hospitals current AMG systems. The order value amounts to approximately SEK 300 thousand and delivery will take place during the current month.

Senzime communicates strategic and financial goals

Press release: Uppsala, September 23, 2020. Senzime AB (publ) today announces the company’s strategic and financial goals for 2023. 

Senzime secures large order on single use sensors from South Korea

Press release: Uppsala, September 15, 2020. Senzime AB (publ) today announces that the company has received another order from its distributor in South Korea. The order value amounts to approximately SEK 1 million and refers only to single use TetraSens sensors. The order will be processed during the current month.

TetraGraph connects surgical data to the cloud

Press release: Uppsala, August 24th, 2020. Senzime AB (publ) today announces the launch of TetraConnect, a novel cloud-based platform allowing physicians to graphically visualize and share patient data when using the TetraGraph monitor.

Senzime’s Interim report January – June 2020

Press release: Uppsala, August 21, 2020. Senzime AB’s (publ) Interim report for January – June 2020 is now available on the company’s website  www.senzime.com

CEO Pia Renaudin buys shares for SEK 5.5 million in Senzime

Press release: Uppsala, July 17th, 2020. Senzime AB (publ) today announces that CEO Pia Renaudin has acquired 300,000 shares in the company at a price of SEK 18.50 per share, corresponding to a value of approximately SEK 5.5 million. The shares have been acquired from a consortium of principal owners consisting of Segulah Venture AB, Adam Dahlberg and Philip Siberg (through company).

Senzime invitation to new website

NEWS: Uppsala, July 13, 2020. Senzime AB (publ) is delighted to invite customers and visitors to explore our new website, designed to offer a user-friendly experience.

Communique from extra general meeting in Senzime AB (publ)

The extra general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 2 July 2020 in Uppsala by postal voting in advance whereby the shareholders primarily resolved on the following matters.

Senzime expands US sales team and signs additional distribution agreements

Press release: Uppsala, June 24, 2020. Senzime AB (publ) today announces that the company has initiated its Sales Ramp Up in the US to establish a direct sales force in key territories and that the company has signed distribution agreements for the Midwest and Northwest territories.

Senzime Joins the Anesthesia Patient Safety Foundation (APSF) as a member of the Corporate Advisory Counsel

NEWS: Uppsala, June 23, 2020. Senzime AB (publ) today announces that they have joined the Anesthesia Patient Safety Foundation (APSF) as a member of the APSF Corporate Advisory Counsel.

Notice of extra general meeting in Senzime AB (Publ)

Press release: Uppsala, June 18, 2020. The shareholders in Senzime AB (publ) corp. reg. no 556565-5734 (the “Company”) are hereby convened to an extra general meeting on Thursday 2 July 2020 in Uppsala. The extra general meeting will be carried out solely through advance postal voting due to the Corona pandemic (Covid-19). This means that the shareholders in the Company may not attend to the general meeting in person nor to be represented by proxy. The shareholders may exercise their voting rights at the general meeting through postal voting in accordance with the instructions in this notice of extra general meeting.

The latest evidence in the Management of Neuromuscular Blockade

News: Uppsala, June 3, 2020. Senzime AB (publ) today announces that they are the proud sponsor of a free webinar on the management of neuromuscular blockade.

Communique from annual general meeting in Senzime AB (publ)

The annual general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 14 May 2020 at Green Innovation Park’s premises on Ulls väg 29C in Uppsala whereby the shareholders primarily resolved on the following matters.

Senzime’s Interim report January – March 2020

Press release: Uppsala, May 8, 2020. Senzime AB’s (publ) Interim report for January – March 2020 is now available on the company’s webbsite  www.senzime.com

Senzime Annual Report 2019

Press release: Uppsala, April 16, 2020. Senzime AB (publ) today announces that the company’s Annual report for year 2019 is now available in Swedish on the company’s website  www.senzime.com

Notice of annual general meeting in Senzime AB (publ)

Press release: Uppsala, April 15, 2020. The shareholders in Senzime AB (publ) corp. reg. no 556565-5734 (the “Company”) are hereby convened to an annual general meeting on Thursday 14 May 2020 at 16.00 at Green Innovation Park’s premises on Ulls väg 29C in Uppsala.

Senzime AB carries out a directed share issue and raises SEK 73.5 million before issue costs

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. Press release: Uppsala, April 8, 2020. The Board of Directors of Senzime AB ("Senzime" or the “Company") has utilised the authorisation received at the AGM on 8 May 2019 and resolved on a directed share issue to Fjärde AP-Fonden, Swedbank Robur Microcap, TIN Fonder, Danske Invest Småbolagsfond, Handelsbanken Fonder, Länsförsäkringar Fonder and ÖstVäst Capital Management. The directed share issue comprises 4,900,000 shares at a subscription price of SEK 15 per share, which corresponds to today’s closing price. Through the share issue, the Company is raising SEK 73.5 million before issue costs.

Breakthrough orders for Senzime in the UK

Press release: Uppsala, March 31, 2020. Senzime AB (publ) today announces that the company has received orders for TetraGraph systems and associated disposable sensors from the NHS-hospitals Medway Maritime Hospital and Sherwood Forest Hospital. The initial order value amounts to about SEK 0.5 million.

Senzime secures the first sales in the US market

News: Uppsala, March 30, 2020. Senzime AB (publ) today announces that the company has received its first orders in the US which marks the sales start in the fully owned subsidiary Senzime Inc.

COVID-19 – Update from Senzime

Press release: Uppsala, March 25, 2020. Senzime AB (publ) today announces that there currently are no indications of problems with supply of goods or delays in customer deliveries and that they are working actively with digital channels and educational efforts during the current situation regarding COVID-19.

Senzime’s Year-End Report 2019

Press release: Uppsala, February 2020. Senzime AB’s (publ) Year-End Report for 2019 is now available on the company’s website www.senzime.com.

Correction: Senzime receives new major order from South Korea and passes 400 delivered TetraGraph

Press release: Uppsala, January 7, 2020. Senzime AB (publ) today announces that they have received a new order of TetraGraph systems and single use electrodes from their distributor in South Korea. The order value amounts to approximately 1,5 MSEK and delivery will take place during the current month. (The correction is editorial)

Senzime recruits General Manager to lead US operations

Press release: Uppsala, December 18, 2019. Senzime AB (publ) today announces that the company has recruited Chris Estes as General Manager of the US operations. Chris takes office on January 6, 2020 and will also be a member of the Senzime AB Executive Management team.

Launch of TetraGraph Philips Interface

Press release: Uppsala, December 3, 2019. As previously communicated in a Press release 2018, Senzime AB (publ) signed a license and cooperation agreement with Philips to allow the TetraGraph Neuromuscular Monitoring System to communicate with Philips IntelliVue patient monitors worldwide. The TetraGraph Philips Interface is now ready for launch.

Senzime’s Interim report January – September 2019

Press release: Uppsala, November 8, 2019. Senzime AB’s (publ) Interim report for January – September 2019 is now available on the company’s webbsite  www.senzime.com

New research data proves the value of accurate monitoring of patients after use of muscle relaxants

News: Uppsala, November 4, 2019. New evidence from the POPULAR study concludes that higher TOF-ratio before extubating reduces the risk of postoperative pulmonary complications.

Presented research from Mayo Clinic proves TetraGraph ease of use

News: Uppsala, October 24, 2019. The ASA (American Society of Anesthesiology) Annual Meeting is the premier venue for meeting physician anesthesiologists in the US with 14,000 attendees. During this year’s meeting, Assistant Professor J.Ross Renew MD at the Mayo Clinic in Jacksonville, Florida, held a poster presentation about the ease of application of various neuromuscular devices for routine monitoring.

Senzime receives FDA clearance

Press release: Uppsala, October 18, 2019. Senzime AB (publ) today announces that the company's medical technology system for monitoring neuromuscular blockade, TetraGraph, has received 510 (k) clearance by the US drug authority FDA. The clearance gives permission to market and sell TetraGraph in the US market.

100 TetraGraph systems to Japan after regulatory approval

Press release: Uppsala, August 30, 2019. In December 2016, Senzime AB (publ) signed a ten-year licensing agreement with Japanese Fukuda Denshi on the exclusive right to license and commercialize Senzime's TetraGraph system in the Japanese market. Fukuda are now about to initiate market launch as TetraGraph has obtained regulatory approval from the Japanese authorities. At the same time, Senzime receives a milestone payment of approximately SEK 1.8 million and 100 TetraGraph systems are shipped to Japan.

Senzime’s Interim report January – June 2019

Press release: Uppsala, August 22, 2019. Senzime AB’s (publ) Interim report for January – June 2019 is now available on the company’s webbsite www.senzime.com.

Communique From Extraodrinary General Meeting in Senzime AB (publ)

An extraordinary general meeting in Senzime AB (publ) was held on 21 August 2019 at the company’s offices on Ulls väg 29B in Uppsala whereby the shareholders primarily resolved on the following matters.

Notice of extraordinary general meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to an extraordinary general meeting on Wednesday 21 August 2019 at 15.00 at the Company’s office at Ulls väg 29B in Uppsala.

Senzime AB (publ) proposes a directed share issue of SEK 30 million to Länsförsäkringar, Handelsbanken, Segulah and the Crafoord family

Press release: Uppsala, July 25, 2019. The Board of Directors of Senzime AB (publ) ("Senzime" or the "Company") has decided to propose a directed share issue to a consortium consisting of a few strategically important investors, including Länsförsäkringar funds, Handelsbanken Microcap, Segulah and the Crafoord family to a value of SEK 30 million before issue costs and at a subscription price per share of SEK 8.90, corresponding to the average price in the last three trading days. Through the rights issue, the Company will receive SEK 30 million before issue costs to support the global launch of TetraGraph.

Senzime increases focus on the market for anesthesia monitoring and communicates sales targets

Press release: Uppsala, July 9, 2019. Senzime AB (publ) announces today that the company has chosen to increase its focus on the market for anesthesia monitoring as a result of the increased interest in the company's patient monitor, TetraGraph, which is in a global rollout phase. The company also communicates sales targets for 2019. 

TetraGraph receives regulatory approval and additional order from South Korea

Press release: Uppsala, July 8, 2019. Senzime AB (publ) today announces that TetraGraph has been approved in Korea and that the local distributor has followed up the order in May with an additional order comprising 30 TetraGraph systems.

Senzime contracts new CFO

Press release: Uppsala, June 18, 2019. Senzime AB (publ) today announces that the company has contracted Erik Bergman as new CFO and member of the management team. Erik succeeds Jessica Roxhed as CFO and takes office on October 1, 2019.

Senzime's board member Ulf Lindskog has passed away

Press release: Uppsala, June 7, 2019. It is with great sadness that we today announce that Ulf Lindskog passed away on June 5 after a period of illness at the age of 75. Ulf was elected member of Senzime's Board of Directors in 2010 and has been a highly appreciated member of Senzime's board. Our thoughts go to Ulf's family.

Senzime receives the first million order from South Korea

Press release: Uppsala, March 29, 2019. Senzime AB (publ) today announces that their distributor in Korea, Unimedics, has placed its first order for TetraGraph and its associated consumables at an order value of 1 million SEK due to be delivered during this week.

CFO transition in Senzime

Press release: Uppsala, May 14, 2019. Senzime AB (publ) today announces that Senzimes CFO Jessica Roxhed has resigned for personal reasons and will leave the company in August 2019.

Senzime exhibitor at SAMTIT

News: Uppsala, May 10, 2019. Senzime AB (publ) reports from SAMTIT Congress 8-10 May 2019

Communique from the annual general meeting in Senzime AB (publ)

The annual general meeting in Senzime AB (publ) was held on 8 May 2019 at the company’s offices on Ulls väg 29B in Uppsala whereby the shareholders primarily resolved on the following matters.

Senzime’s Interim report January – March 2019

Press release: Uppsala, May 8, 2019. Senzime AB’s (publ) Interim report for January – March 2018  is now available on the company’s webbsite www.senzime.com.

Senzime signs Nordic distribution agreement with Vingmed Holding A/S

Press release: Uppsala, May 6, 2019. Senzime AB (publ) today announces that it has signed an exclusive distribution agreement with Vingmed Holding A/S for the commercialization of TetraGraph in Sweden, Denmark, Norway and Finland.